Blog

• Warburg Pincus enters exclusive negotiations to acquire a significant minority stake in Sebia
• Existing shareholders CVC Funds, La Caisse (formerly CDPQ) and Téthys Invest to remain significant investors

Sebia, a global leader in specialty diagnostics, and Warburg Pincus, the pioneer of private equity global growth investing, today announced that Warburg Pincus has entered into exclusive negotiations for the potential acquisition of a significant minority stake in Sebia.  

Sebia is a global specialized In Vitro Diagnostics player providing equipment and reagents for the screening and monitoring of various diseases, primarily in the areas of Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathy, Autoimmune and Infectious diseases and other rare pathologies. The company serves customers in more than 140 countries through a broad installed base and a portfolio of proprietary reagents and instruments.

Jean-Marc Chermette, Chief Executive Officer of Sebia, said: “Our mission is to provide powerful tools that translate what is happening in a patient’s body into a readable and interpretable language. We welcome Warburg Pincus as a new partner alongside our existing investor base. Their global healthcare expertise and growth orientation will help accelerate Sebia’s strategy while maintaining our commitment to scientific rigor, product quality and patient impact, helping us deliver for our customers and partners.”

TJ Carella, Managing Director and Global Head of Healthcare, and Jake Strauss, Managing Director and Head of European Healthcare at Warburg Pincus, said: “Sebia is a best-in-class diagnostics platform with differentiated technology and a strong track record of delivering innovative products and solutions to customers and patients worldwide. We are excited to partner with Jean-Marc, the management team, and existing shareholders to support the company’s next phase of growth, including continued advances in diagnostic modalities, scientific excellence and manufacturing capabilities.”

The terms of the proposed transaction are not disclosed. Following completion, Sebia will continue to operate as an independent company from its headquarters in Lisses, France.

Execution of the proposed transaction remains subject to completion of applicable employee consultation processes, and receipt of customary regulatory approvals. Closing is expected to occur no earlier than Q1 2026.

Amazon One Medical Pay-per-visit currently focuses on treating pink eye, head lice, and common kids’ skin issues, including eczema, contact dermatitis, impetigo, fungal rashes (e.g., ringworm), bug bites, hand-foot-and-mouth disease, fifth disease, roseola, poison ivy, and diaper rash. Parents can also renew their kids’ EpiPen and asthma medications.